期刊
LEUKEMIA
卷 27, 期 1, 页码 213-219出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2012.197
关键词
heavy/light chain assay; multiple myeloma; monoclonal immunoglobulin; response evaluation and prognostication
资金
- Austrian Forum Against Cancer
The novel heavy/light chain (HLC) assay was used for the detection and measurement of monoclonal immunoglobulins, response evaluation and prognostication. This test allows identification and quantification of the different light chain types of each immunoglobulin class (for example, IgG kappa and IgG lambda) and enables calculation of ratios of monoclonal/polyclonal immunoglobulin (HLC ratio). Sequential sera of 156 patients with IgG or IgA myeloma started on first-line therapy and followed for a median of 46.1 months were analyzed. Results were compared with those obtained with conventional techniques (serum protein electrophoresis (SPEP), immunofixation electrophoresis (IFE), nephelometry (NEPH), and the free light chain test (FLC)). Our data show that the HLC assay allowed quantification of monoclonal proteins not accurately measurable by SPEP or NEPH. When both HLC and FLC testing were applied for response assessment, clonal excess was noted in 14/31 patients with complete response (CR). HLC ratio indicated presence of disease in 8/31 patients who achieved CR and, in sequential studies indicated evolving relapse in three patients before IFE became positive. Highly abnormal HLC ratios at presentation were significantly associated with shorter overall survival (40.5 months vs median not reached, P = 0.016). Multivariate analysis revealed HLC ratio (P = 0.03) and beta(2)-microglobulin (P<0.01) as independent risk factors for survival. Leukemia (2013) 27, 213-219; doi: 10.1038/leu.2012.197
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据